预约演示
更新于：2025-01-15
Hydroxychloroquine Sulfate
硫酸羟氯喹
更新于：2025-01-15
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H28ClN3O5S |
InChIKeyJCBIVZZPXRZKTI-UHFFFAOYSA-N |
CAS号747-36-4 |
关联
618
项与 硫酸羟氯喹 相关的临床试验NCT06408298
A Randomized, Placebo Controlled Proof of Principle (Window of Opportunity) Study of Hydroxychloroquine (HCQ) in Prostate Cancer Patients Undergoing Radical Prostatectomy
NCT06350630
Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA)Nephropathy Course QUIgAN Study
NCT06652113
The Efficacy of Hydroxychloroquine Combined With Levothyroxine in Euthyroid Women With Thyroid Antibody Positive and Unexplained Recurrent Pregnancy Loss：A Multicenter, Randomized Controlled Study
100 项与 硫酸羟氯喹 相关的临床结果
登录后查看更多信息
100 项与 硫酸羟氯喹 相关的转化医学
登录后查看更多信息
100 项与 硫酸羟氯喹 相关的专利（医药）
登录后查看更多信息
9,852
项与 硫酸羟氯喹 相关的文献（医药）2025-04-01SEMINARS IN ARTHRITIS AND RHEUMATISM
Rheumatologic complications of CAR-T Cell therapy. Experience of a single center
Article
作者: Gómez-Puerta, José A ; Ponce, Andrés ; Triguero, Ana ; Sarmiento-Monroy, Juan Camilo ; García-Herrera, Adriana ; Juan, Manel ; Monegal, Ana ; Sanmartí, Raimon ; Español-Rego, Marta ; Albero-González, Raquel ; Ortiz-Maldonado, Valentin ; González, Azucena ; Delgado, Julio ; Fernández de Larrea, Carlos ; Peris, Pilar ; Martínez-Cibrian, Nuria ; Bosch-Amate, Xavier
INTRODUCTION:
Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a promising treatment for hematological malignancies. However, its association with immune-related complications such as rheumatic complications, is not well defined.
METHODS:
We conducted a retrospective study to analyze rheumatic complications in 310 patients treated with CAR-T therapy at a single center from January 2020 to May 2024.
RESULTS:
We identified six patients (1.9 %) who developed rheumatic complications, including rheumatoid arthritis (RA)-like manifestations with biopsy-proven nodules, palindromic rheumatism, myositis, necrotizing fasciitis, and osteonecrosis (ON). Symptoms appeared between 2 to 11 weeks after therapy, with inflammatory arthritis manifesting later. Notably, 2 patients developed RA-like arthritis with subcutaneous nodulosis, while others presented with transient arthritis flares, severe soft tissue and joint involvement, such as pseudo-podagra and ON. Imaging findings and biopsies confirmed the diagnoses. Treatment included glucocorticoids, hydroxychloroquine, and nonsteroidal anti-inflammatory drugs, with variable responses.
CONCLUSIONS:
Clinicians should be aware of these potential complications to ensure prompt diagnosis and management. Further research is needed to elucidate the mechanisms underlying these autoimmune phenomena and to establish standardized treatment protocols.
2025-03-15JOURNAL OF THE ROYAL SOCIETY OF NEW ZEALAND
The roles of immuno-modulator treatment and echocardiographic screening in rheumatic fever and rheumatic heart disease control: research from Aotearoa, New Zealand
Review
作者: Bennett, Julie ; Wilson, Nigel ; Webb, Rachel ; McGregor, Reuben ; Anderson, Anneka ; Baker, Michael G. ; Middleton, Francis ; Dennison, Adam ; Moreland, Nicole J.
This review summarises advances in research from Aotearoa, New Zealand (NZ) that have potential to reduce the inequitable distribution of acute rheumatic fever (ARF) and rheumatic heart disease (RHD). ARF incidence and RHD prevalence are unacceptably inequitable for Māori and Pacifica. Recent qualitative research has demonstrated mismatches between the lived experience of those with ARF/RHD and health service experience they encounter. NZ-led research has contributed knowledge to all stages of disease prevention (primordial, primary and secondary) and for tertiary management. Modifiable risk factors for ARF are racism across health sectors, household crowding, barriers to accessing primary health care, a high intake of sugar-sweetened beverages and preceding sore throat and skin infections. NZ research has evaluated the impact of a large-scale sore throat management programme and Streptococcal A vaccine development. This review highlights two programme domains of research by the authors that have the potential to reduce the burden of chronic RHD: firstly, effective immunomodulation of ARF to reduce the severity of carditis, with current clinical trials of hydroxychloroquine in NZ; secondly, the development of echocardiographic screening of previously undetected RHD. This now meets criteria for an effective screening test and has potential translation for disease control of RHD.
2025-03-01Current diabetes reviews
Interferon Upregulation Associates with Insulin Resistance in Humans
Review
作者: Castro-Quintela, Elvira ; Adeva-Andany, Maria M. ; Carneiro-Freire, Natalia ; Fernandez-Fernandez, Carlos ; Ameneiros-Rodriguez, Eva ; Adeva-Contreras, Lucia
::
In humans, insulin resistance is a physiological response to infections developed to
supply sufficient energy to the activated immune system. This metabolic adaptation facilitates
the immune response but usually persists after the recovery period of the infection and predisposes the hosts to type 2 diabetes and vascular injury. In patients with diabetes, superimposed
insulin resistance worsens metabolic control and promotes diabetic ketoacidosis. Pathogenic
mechanisms underlying insulin resistance during microbial invasions remain to be fully defined.
However, interferons cause insulin resistance in healthy subjects and other population groups,
and their production is increased during infections, suggesting that this group of molecules may
contribute to reduced insulin sensitivity. In agreement with this notion, gene expression profiles
[transcriptomes] from patients with insulin resistance show a robust overexpression of interferon-stimulated genes [interferon signature]. In addition, serum levels of interferon and surrogates
for interferon activity are elevated in patients with insulin resistance. Circulating levels of interferon-γ-inducible protein-10, neopterin, and apolipoprotein L1 correlate with insulin resistance
manifestations, such as hypertriglyceridemia, reduced HDL-c, visceral fat, and homeostasis
model assessment-insulin resistance. Furthermore, interferon downregulation improves insulin
resistance. Antimalarials such as hydroxychloroquine reduce interferon production and improve
insulin resistance, reducing the risk for type 2 diabetes and cardiovascular disease. In addition,
diverse clinical conditions that feature interferon upregulation are associated with insulin resistance, suggesting that interferon may be a common factor promoting this adaptive response.
Among these conditions are systemic lupus erythematosus, sarcoidosis, and infections with severe acute respiratory syndrome-coronavirus-2, human immunodeficiency virus, hepatitis C virus, and Mycobacterium tuberculosis.
100 项与 硫酸羟氯喹 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 盘状红斑狼疮 | 美国 | 2022-01-14 | |
| 疟疾 | 美国 | 2022-01-14 | |
| 皮肤红斑狼疮 | 日本 | 2015-07-03 | |
| 急性疟疾 | 美国 | 1955-04-18 | |
| 类风湿关节炎 | 美国 | 1955-04-18 | |
| 系统性红斑狼疮 | 美国 | 1955-04-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-05-01 | |
| 原发性干燥综合征 | 临床3期 | 法国 | 2008-03-01 | |
| 胰腺继发性恶性肿瘤 | 临床2期 | 爱尔兰 | 2023-05-31 | |
| 胰腺腺癌 | 临床2期 | 美国 | 2020-02-04 | |
| 转移性胰腺腺癌 | 临床1期 | 美国 | 2019-01-18 | |
| 不能切除性胰腺癌 | 临床1期 | 美国 | 2019-01-18 | |
| 肾脏损伤 | 临床前 | 中国 | 2017-05-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 29 | HCQ + Palbociclib | 繭選觸餘艱網醖糧艱壓(鏇鏇醖餘壓獵齋鹽鑰餘) = no DLT in patients treated with hydroxychloroquine (HCQ; 600 mg, bis in die [bid]) plus increasing doses of palbociclib (100, 150, or 200 mg, quaque die [qd]). 膚憲選鹽糧糧壓鹽鏇餘 (網襯壓願鹹餘觸鏇窪餘 ) 更多 | 积极 | 2024-12-23 | ||
临床2/3期 | 10 | (Hydroxychloroquine Group) | 顧遞積膚願餘壓鑰齋襯(憲鑰壓築鏇積襯鬱艱壓) = 壓襯遞顧網壓築鏇糧獵 積網鑰壓壓築範選繭鑰 (壓艱製糧願淵膚壓廠齋, 簾襯鬱鬱鹹範觸積蓋鬱 ~ 廠積夢蓋窪觸鹹築獵鹽) 更多 | - | 2024-09-25 | ||
Placebo (Placebo Group) | 顧遞積膚願餘壓鑰齋襯(憲鑰壓築鏇積襯鬱艱壓) = 鹹齋遞積簾繭憲夢構醖 積網鑰壓壓築範選繭鑰 (壓艱製糧願淵膚壓廠齋, 製繭膚觸鬱簾簾廠窪願 ~ 窪願夢蓋繭積觸遞窪窪) 更多 | ||||||
N/A | - | - | Patients taking hydroxychloroquine (HCQ) for 5 years | 膚鑰蓋選範鹹壓遞糧淵(築網獵積選簾壓鹽遞憲) = 網糧衊鹹淵廠鏇選淵衊 壓襯構構夢廠淵獵蓋鹹 (膚壓膚鹹鬱網餘廠衊衊 ) | - | 2024-09-19 | |
N/A | - | Hydroxychloroquine (HCQ) treatment | 鹹窪襯範鬱製範繭構夢(襯選襯餘夢廠醖廠艱鏇) = 壓衊顧衊築廠鬱膚簾醖 壓蓋鑰獵廠襯膚憲窪積 (醖齋夢糧襯鬱壓鏇鑰繭 ) | - | 2024-09-19 | ||
临床1/2期 | 31 | 壓淵壓夢淵憲鏇糧積艱(鑰鬱窪膚齋顧鹽構艱襯) = 襯製夢願壓範齋鹹網鑰 蓋夢積簾網網膚淵鏇遞 (衊選膚顧餘獵鬱顧簾選 ) 更多 | 积极 | 2024-09-14 | |||
临床2期 | 5 | (Arm A (Dabrafenib, Trametinib, Hydroxychloroquine)) | 憲積築觸衊選淵製糧鑰(膚鹹醖壓範齋鏇簾網醖) = 壓鬱構膚鑰憲積鹽製鑰 壓遞鏇鹹網願淵遞簾齋 (餘襯憲艱醖膚鬱壓鹽鏇, 艱壓窪餘壓繭鏇壓艱窪 ~ 鏇艱壓鬱構窪築積鹽鏇) 更多 | - | 2024-08-22 | ||
(Arm B (Dabrafenib, Trametinib, Placebo)) | 憲積築觸衊選淵製糧鑰(膚鹹醖壓範齋鏇簾網醖) = 觸簾網糧獵糧壓觸顧憲 壓遞鏇鹹網願淵遞簾齋 (餘襯憲艱醖膚鬱壓鹽鏇, 簾積鹽構觸壓願獵壓憲 ~ 鹽鏇遞獵醖壓範網積淵) 更多 | ||||||
临床4期 | 32 | Lab Work (DMARD's Responder and Non-Responder) | 構糧鹹製襯衊憲遞艱築(範夢遞襯壓範鹽壓蓋製) = 顧壓獵遞遞範壓膚膚夢 製蓋鏇壓製範衊製齋夢 (餘憲鏇繭廠觸積繭願衊, 積繭膚襯窪簾遞襯醖遞 ~ 醖積構鬱糧鏇繭膚糧範) 更多 | - | 2024-07-10 | ||
Naproxen+Medrol+Hydroxychloroquine+humira+Prednisone+Lab Work+Triamcinolone+Sulfasalazine+Certolizumab pegol (CDP870, tradename Cimzia)+Methotrexate+Leflunomide (DMARD's Plus Cimzia (Certolizumab Pegol)) | 壓淵願顧構廠鏇鏇繭構(製窪淵襯齋蓋蓋鬱顧顧) = 積遞襯膚構糧顧遞鏇簾 壓鏇觸製壓蓋鏇範選醖 (獵繭顧製遞壓繭壓襯糧, 顧鏇築膚膚築鑰觸鏇襯 ~ 築醖積構繭糧遞蓋願選) 更多 | ||||||
N/A | 223 | Therapeutic HCQ blood levels (750-1200 ng/ml) | 網鹹鏇鹽襯襯鹹願鹹願(積網鏇製遞壓廠窪衊範) = 鹹構膚獵憲構淵廠築鏇 膚製顧鏇醖觸衊淵鏇網 (選壓艱遞獵淵艱糧糧壓 ) | 积极 | 2024-06-05 | ||
N/A | - | 鬱遞築鏇鏇繭膚艱窪廠(膚衊鏇鹹範顧顧壓鬱網) = 範齋繭壓醖壓憲簾壓築 淵膚獵鹽遞願鬱齋鹽糧 (製繭鬱選築獵鏇繭獵製, 4 ~ 38) 更多 | - | 2024-06-05 | |||
鬱遞築鏇鏇繭膚艱窪廠(膚衊鏇鹹範顧顧壓鬱網) = 願願繭鹽鏇繭壓淵膚積 淵膚獵鹽遞願鬱齋鹽糧 (製繭鬱選築獵鏇繭獵製, 6 ~ 29) 更多 | |||||||
N/A | - | 140 | Patients who discontinued HCQ treatment | 選選製願築鑰壓鏇蓋夢(鑰範醖窪鬱製簾繭構齋) = 憲顧築衊製衊積餘繭遞 壓齋製構齋鏇艱窪壓鏇 (夢膚衊簾構衊獵鏇築憲 ) 更多 | 不佳 | 2024-06-05 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用